An evaluation of the response to neoadjuvant chemotherapy for osteosarcoma of extremities: PERCIST versus RECIST 1.1 criteria after long-term follow-up
ConclusionOur data indicate that the PERCIST criteria are significantly more sensitive than RECIST 1.1 criteria to identify more responders when evaluating the response of osteosarcoma to neoadjuvant chemotherapy.
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research
More News: Bone Cancers | Chemotherapy | CT Scan | MRI Scan | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Nuclear Medicine | Osteosarcoma | PET Scan | Study